Health and Healthcare
Biotech Business Daily (BIIB, VRTX, ALNY, STEM)
Published:
Last Updated:
Here are some of the top stories affecting key drug and biotech stocks this Friday. We also have links through to more detailed coverage and analysis at BioHealthInvestor.com:
Biogen Idec Inc. (Nasdaq: BIIB) kicks off the earnings season for the large biotech companies next week. We have a full earnings preview with current expectations and the bias. A decline in analyst sentiment for the stock might set up the company for a slight earnings surprise, on the back of recent price increases for its high-profile multiple sclerosis drug Avonex.
Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) this morning said it will sell its rights to milestone payments tied to its hepatitis C drug telaprevir in Europe, a possible sign that the launch of the drug with partner Johnson & Johnson (NYSE: JNJ) for 2011 may be on track.
Also, see our in-depth feature this week on five fast-growing biotechs with improving analyst estimates: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM).
-The 24/7 Wall St. Team
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
